Jump to start of content

ABIM Scheduled Maintenance... Expand/Collapse the ABIM alert.

ABIM.org will be going through scheduled maintenance from 6 p.m. ET, Sat., 11/17 to 6 a.m. ET, Sun., 11/18. During this time, the ABIM Physician Portal will be unavailable. We apologize for any inconvenience this may cause. Thank you for your patience.

Fall 2018 Exams affected by Wildfires in California Expand/Collapse the ABIM alert.

ABIM knows that we have physicians whose lives may have been upended by wildfires in California. If you live or work in affected areas, we understand that this may have impacted your ability to take your Fall 2018 exam as scheduled. We have options to help you get through this process as smoothly as possible. If you have any questions please call us at 1-800-441-ABIM (2246) or email request@abim.org.

Breadcrumb trail:

Endocrinology, Diabetes, & Metabolism Board

Expand All | Collapse All

Ashok Balasubramanyam, MD, Chair

Ashok Balasubramanyam, MDDr. Balasubramanyam, a board certified internist and endocrinologist, is Professor of Medicine in the Division of Diabetes, Endocrinology and Metabolism, Vice President for Academic Integration and Senior Associate Dean for Academic Affairs at Baylor College of Medicine, Houston. His academic career involves basic and translational research in diabetes and metabolic diseases, education (including service as past director of the endocrine fellowship program and current director of Baylor’s Clinical Scientist Training Program), and clinical practice as an internist and endocrine consultant.

Currently, Dr. Balasubramanyam serves as a member of the ABIM Council and the Chair of the Endocrinology, Disease, and Metabolism Board of the American Board of Internal Medicine. He is a past president of the Association of Program Directors in Endocrinology and Metabolism.

Dr. Balasubramanyam earned his undergraduate degree at Yale University and his medical degree at St. John’s Medical College, Bangalore, India. He completed residency training and was Chief Resident at Baylor College of Medicine, and completed clinical and research fellowship training in endocrinology at the Massachusetts General Hospital, Boston.

As of February 2018, Dr. Balasubramanyam reported the following external relationship:

Work as an author or editor for the following company, with compensation as listed below:

  • UpToDate, receiving compensation for authorship.

Gary Bloom

Mr. Bloom, a thyroid cancer survivor, is co-founder and Executive Director of ThyCa: Thyroid Cancer Survivors’ Association, Inc., where he directs the overall organization, including: operational, technological, and financial management, and maintains collaborations with numerous professional, patient, and community organizations. He works closely with the ThyCa Volunteer Board of Directors and committee coordinators. He leads committee development and directs fundraising. He also develops the program for the Annual International Thyroid Cancer Survivors' Conference and recruits all professional speakers. He is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board.

Previously, Mr. Bloom served as an Applications Engineer for Eclipsys Corporation where he designed and implemented workflow streamlining applications for large health care organizations. He also developed custom and standard reports, and prepared teaching materials and trained clients in the use of Eclipsys’ database structure and reporting system.

Mr. Bloom also served as Controller and Director of Operations at Intelus where he was responsible for all financial, human resources, and administrative responsibilities. He was responsible for all financial activity and financial reporting to management, venture capital investors, and the Board of Directors. Additionally, he secured and managed employee benefits, facility space requirements, office insurance and security.

Mr. Bloom received a a bachelor's degree in accounting from the University of Vermont.

As of July 2017, Mr. Bloom reported the following external relationships:

Mr. Bloom serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • ThyCa: Thyroid Cancer Survivors' Association, Inc., Executive Director, receiving compensation and reimbursement for travel expenses.

Marjorie Ewertz, RN, BSN

Ms. Ewertz is on the Faculty of the Johns Hopkins University School of Medicine, Division of Endocrinology, Diabetes and Metabolism. She served as the Director of Clinical Operations for four years, until 2016, working closely with physicians, nurses and fellows. She is a member of the Fellows Advisory Committees. A proponent of the electronic medical records, Ms. Ewertz took the lead implementing EPIC for the Division of Endocrinology.

Ms. Ewertz has been involved in education, research and patient care for Johns Hopkins Medicine since 1994 as an endocrine nurse. Previously, Ms. Ewertz served as Adjunct Faculty of the Johns Hopkins University School of Nursing. She was also on the faculty of the St. Joseph Hospital and Union Memorial Hospital Schools of Nursing, teaching Medical Surgical Nursing and Critical Care.

Ms. Ewertz serves as a member of the American Board of Internal Medicine for Endocrinology, Diabetes, and Metabolism Board. She was the first nurse accepted for membership to the American Thyroid Association in 2003 and has been on the Clinical Affairs Committee. She was a member of the Endocrine Society and served on the Hormone Foundation Committee. Ms. Ewertz has served the Endocrine Nurses Society as President and Chairman of the Program and Development Committees since 1994.

Ms. Ewertz received her bachelor's degree in nursing from the University of Maryland School of Nursing.

As of January 2017, Ms. Ewertz reported no external relationships.

Paul W. Ladenson, MD

Dr. Ladenson, a board certified internist and endocrinologist, is the John Eager Howard Professor of Endocrinology and Metabolism and Director of the Division of Endocrinology, Diabetes, & Metabolism at the Johns Hopkins Medical Institutions, where he is Professor of Medicine, Pathology, Oncology, and Radiology and Radiological Sciences, as well as a University Distinguished Professor. He is also Professor of International Health at the Johns Hopkins Bloomberg School of Public Health. His academic career has been as a clinical investigator and educator in thyroidology, and his principal research interests have been thyroid hormone actions on the heart, thyroid cancer, thyroid hormone analogs and health economic analyses related to clinical endocrinology.

Dr. Ladenson serves as a member of the American Board of Internal Medicine (ABIM) Endocrinology, Diabetes, and Metabolism Board as well as the ABIM Endocrinology, Diabetes, and Metabolism Board Exam Committee. He is past Editor-in-Chief of the Journal of Clinical Endocrinology & Metabolism and has served in the past as President of the Association of Program Directors in Endocrinology and Metabolism, the Association of Subspecialty Professors and the American Thyroid Association.

Dr. Ladenson graduated summa cum laude from Dartmouth College with a degree in English literature, from Oxford University with a degree in physiology, and from Harvard Medical School. He trained as a resident in internal medicine and as a clinical and research fellow in endocrinology at Massachusetts General Hospital.

As of January 2017, Dr. Ladenson reported the following external relationships:

Service on a research-related expert panel or advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Veracyte, providing advice regarding clinical and health-economic research related to molecular genetic testing for differential diagnosis of thyroid nodules, receiving compensation for travel expenses and honoraria.
  • Viking Therapeutics, providing advice regarding preclinical and clinical research related to applications of thyromimetic compounds to metabolic disorders, receiving honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, receiving honoraria:

  • Sentier Therapeutics, for providing advice regarding preclinical and clinical research related to compounds for thyroid hormone therapy.
  • Veracyte, receiving support for lectures to regional professional societies.

Jonathan D. Leffert, MD

Dr. Leffert is a board certified clinical endocrinologist and Managing Partner of North Texas Endocrine Center in Dallas, Texas. He has been in private single specialty group or solo practice for the last 25 years, where his passion for excellent patient care drives him daily in his clinical and organizational activities.

Dr. Leffert has been active in organizational medicine since 2000, serving on the board of his county medical society, state medical society Political Action Committee, and now as President of the American Association of Clinical Endocrinologists (AACE). In addition, he is currently the Delegate to the American Medical Association (AMA) for AACE. At the AMA House of Delegates Meeting in 2013, Dr. Leffert led a coalition that resulted in the designation of obesity as a disease. He is also a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board.

Dr. Leffert received a degree in biology from Brown University and his medical degree from the University of Minnesota.

He completed his internship and residency in internal medicine at UT Southwestern/Parkland Memorial Hospital. Dr. Leffert began his research fellowship by studying genes that regulate carbohydrate metabolism in the Touchstone Diabetes Center and completed his clinical fellowship in endocrinology, diabetes and metabolism at UT Southwestern Medical Center in Dallas.

As of January 2017, Dr. Leffert reported the following external relationships:

Funding for clinical trial expenses and staff, paid to North Texas Endocrine Center, from the following companies:

  • AbbVie, for a study of atrasentan on type 2 diabetes with nephropathy.
  • Boehringer Ingelheim, for a study of empagliflozin added to insulin for subjects with type 1 diabetes.
  • Mylan, for a study of glargine injections on type 1 diabetes.
  • Novo Nordisk, for multiple type 1 and type 2 diabetes trials with new insulin analogs.
  • Sanofi, for multiple trials involving type 2 diabetes with insulin glargine injections and type 1 or type 2 diabetes with hypercholesterolemia.

Dr. Leffert serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Association of Clinical Endocrinologists, President, without compensation.

Susan J. Mandel, MD, MPH

Dr. Mandel, a board certified endocrinologist, is Professor of Medicine and Radiology at the Perelman School of Medicine at the University of Pennsylvania, where she also directs the Endocrine Fellowship Program. She serves as the Associate Chief of the Division of Endocrinology, Diabetes, and Metabolism at the Hospital of the University of Pennsylvania, where she directs the Thyroid Cancer Program and the Thyroid Nodule Clinic. Her research interests include the use of sonography in the evaluation of patients with thyroid nodules and as surveillance for those with thyroid cancer and thyroid disease during pregnancy. She has been invited to lecture throughout the United States and internationally on these topics.

Currently, Dr. Mandel is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board. She is also a member of The Endocrine Society, where she currently holds the position of Vice President Physician in Practice; the American Association of Clinical Endocrinologists; and the American Thyroid Association. She is a past President of the Association of Program Directors in Endocrinology, Diabetes, and Metabolism. Dr. Mandel has served on the writing groups for both the American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer and The Endocrine Society Guideline for the Management of Thyroid Disease during Pregnancy. She directs the Introductory and Advanced Ultrasound Workshops for The Endocrine Society.

Dr. Mandel has won prestigious awards for her education and clinical research accomplishments, including the 2011 Endocrine Society's Laureate Distinguished Educator Award, the 2012 H. Jack Baskin Educator Award of the American Association of Clinical Endocrinologists, and the George Murray Lectureship Award from the British Thyroid Association. She has authored articles in the New England Journal of Medicine, the Annals of Internal Medicine, and JAMA, as well as articles in endocrine and radiology journals.

After graduating from Harvard College, she received her medical degree from the College of Physicians and Surgeons, Columbia University, where she also completed her internal medicine residency. She received her fellowship training in endocrinology at the Brigham and Women's Hospital.

As of January 2017, Dr. Mandel reported no external relationships.

Alyson K. Myers, MD

Dr. Myers is a Clinical Educator and the Medical Director of Inpatient Diabetes at North Shore University Hospital in Manhasset, New York. She is also an Assistant Professor at the David and Barbara Zucker School of Medicine at Hofstra/Northwell. She is board certified in both Internal Medicine and Endocrinology, Diabetes and Metabolism.

From 2015-2017, Dr. Myers was accepted as an Empire Clinical Research Investigators Program (ECRIP) fellow. As an ECRIP fellow, she conducted a feasibility study exploring the use of telehealth for lifestyle modification and improved glycemic control in black and Hispanic patients with uncontrolled type 2 diabetes.

Dr. Myers is a member of the American Board of Internal Medicine Endocrinology, Diabetes and Metabolism Board. She is an active member of the Endocrine Society as an abstract reviewer, member of the Clinical Affairs Core Committee, CME course reviewer and a presenter for the Early Career Forum in 2016 and 2017. In 2018, she has been honored as a Rudy W. Powell Awardee by the Kappa Omicron Chapter of Omega Psi Phi Fraternity, Incorporated and with the Michael Kors Educational Advancement Award by the Advancing Women in Science and Medicine at the Feinstein Institute for Medical Research Northwell Health.

Dr. Myers attended the University of Virginia where she majored in French and minored in Chemistry. She attended State University of New York Downstate for medical school, where she was the four-year recipient of the President's Award Scholarship. She completed a five-year combined internal medicine/psychiatry residency at Rush University Medical Center in Chicago, Illinois. During her fourth year, she served as chief resident. In 2012, she completed an endocrinology fellowship at the University of Texas Southwestern. During fellowship, she received a T32 training grant in the area of mood disorders under the mentorship of Dr. Madhukar Trivedi.

As of July 2018, Dr. Myers reported no external relationships.

Christine Twining, MD

Dr. Twining is a board certified endocrinologist and Medical Director at the Maine Medical Partners Center for Endocrinology and Diabetes, a group of eight endocrinologists in Scarborough, Maine. She practices general endocrinology with a focus on thyroid disease, metabolic bone disease and transitional care. Additionally, Dr. Twining is an Assistant Professor of Medicine at Tufts School of Medicine and enjoys teaching Tufts medical students and residents at Maine Medical Center, where she also serves as an advisor to internal medicine-pediatrics residents.

She has been a member of the board of directors for the American Association of Clinical Endocrinologists (AACE) since 2015. She served as AACE's representative to the Young Physicians Section of the AMA from 2010-2015 and served as the Fellow-in-Training Representative to the Board of Directors in 2007-2008. Dr. Twining served on the board of the New England Chapter of AACE and was its president in 2013-2014. She has served on many AACE committees, including Endocrine Training Support, Socioeconomics, Chapters, Membership, Pediatric Endocrinology, and Endocrine University and the Task Force on Women in Endocrinology, among others. Currently, she is a member of the American Board of Internal Medicine Endocrinology, Diabetes, and Metabolism Board.

Dr. Twining has an artium baccalaureus degree from Harvard College and graduated from Duke University School of Medicine. She completed a combined internal medicine-pediatrics residency at Yale followed by an endocrinology fellowship at the University of South Carolina.

As of July 2018, Dr. Twining reported the following external relationships:

Dr. Twining serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Association of Clinical Endocrinologists, Board Member, without compensation.